296 Results for "

Drug resistance

" in MedChemExpress (MCE) Product Catalog:
Products (296)

296 Results for "Drug resistance" in MCE Product Catalog:

132
132 Publications Verification
Cat. No.: HY-15244
CAS No.: 1217486-61-7
Purity:  99.88%
Synonyms: BYL-719
Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .
loading...
    loading...
132
132 Publications Verification
Cat. No.: HY-15244A
CAS No.: 1584128-91-5
Synonyms: BYL-719 hydrochloride
Alpelisib (BYL-719) hydrochloride is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib hydrochloride also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib hydrochloride not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib hydrochloride can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-12874
CAS No.: 425399-05-9
Purity:  99.89%
Target:  

Ras Apoptosis

Research Areas:  

Cancer

CASIN is a selective GTPase Cdc42 inhibitor with an IC50 of 2 uM. CASIN can be used for the research of cancer .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-B1329
CAS No.: 65710-07-8
Synonyms: Nebramycin II sulfate
Apramycin (EBL 1003) sulfate is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin sulfate is a potential anti-drug-resistance antibiotic .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-17558
CAS No.: 37321-09-8
Synonyms: Nebramycin II
Target:  

Bacterial Antibiotic

Research Areas:  

Infection

Apramycin (Nebramycin II) is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin is a potential anti-drug-resistance antibiotic .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-W001132
CAS No.: 120-72-9
Indole is an aromatic, heterocyclic, organic compound which widely distributed in the natural environment and can be produced by a variety of bacteria. Indole regulates various aspects of bacterial physiology, including spore formation, plasmid stability, resistance to drugs, biofilm formation, and virulence as an intercellular signal molecule .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-109061
CAS No.: 1903008-80-9
Purity:  99.87%
Synonyms: YH25448; GNS-1480
Lazertinib (YH25448; GNS-1480) is an orally active, blood-brain barrier permeable third-generation EGFR tyrosine kinase inhibitor, as well as an ABCB1/ABCG2 inhibitor and a TRPA1 activator. Lazertinib exhibits IC50 values of 0.4 mM and 0.2 mM against human ABCB1 and ABCG2, respectively. By inhibiting mutant EGFR signaling, EGFR phosphorylation and the downstream ERK/AKT pathway, as well as upregulating surface expression of EGFR/MET, Lazertinib induces cell cycle arrest, apoptosis, spontaneous calcium responses, hyperexcitability of dorsal root ganglion (DRG) neurons, and TRPA1-dependent pain-like behaviors. Lazertinib competitively binds to the substrate-binding sites of ABCB1/ABCG2, stimulates their ATPase activity without altering their expression or plasma membrane localization, thereby enhancing ADCC activity, acting as a chemosensitizer, and reversing ABCB1-mediated multidrug resistance. It exerts antitumor activity as a single agent or in combination with other drugs. Lazertinib is applicable to research related to non-small cell lung cancer, multidrug-resistant cancers, and paresthesia .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-109061B
CAS No.: 2247995-37-3
Synonyms: YH25448 mesylate; GNS-1480 mesylate
Research Areas:  

Cancer

Lazertinib (YH25448; GNS-1480) mesylate is an orally active, blood-brain barrier permeable third-generation EGFR tyrosine kinase inhibitor, as well as an ABCB1/ABCG2 inhibitor and a TRPA1 activator. Lazertinib mesylate exhibits IC50 values of 0.4 mM and 0.2 mM against human ABCB1 and ABCG2, respectively. By inhibiting mutant EGFR signaling, EGFR phosphorylation and the downstream ERK/AKT pathway, as well as upregulating surface expression of EGFR/MET, Lazertinib mesylate induces cell cycle arrest, apoptosis, spontaneous calcium responses, hyperexcitability of dorsal root ganglion (DRG) neurons, and TRPA1-dependent pain-like behaviors. Lazertinib mesylate competitively binds to the substrate-binding sites of ABCB1/ABCG2, stimulates their ATPase activity without altering their expression or plasma membrane localization, thereby enhancing ADCC activity, acting as a chemosensitizer, and reversing ABCB1-mediated multidrug resistance. It exerts antitumor activity as a single agent or in combination with other drugs. Lazertinib mesylate is applicable to research related to non-small cell lung cancer, multidrug-resistant cancers, and paresthesia .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-107643
CAS No.: 313397-13-6
Purity:  99.90%
Synonyms: CBLC4H10
Target:  

P-glycoprotein

Research Areas:  

Cancer

Reversan (CBLC4H10) inhibits drug efflux mediated by P-glycoprotein (Pgp) and multidrug resistance protein 1 (MRP1), and exhibits oral activity. Reversan shows activity against glioblastoma multiforme and neuroblastoma models .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12333
CAS No.: 1457983-28-6
Purity:  ≥98.0%
Synonyms: G-749
Target:  

FLT3 Apoptosis

Research Areas:  

Cancer

Denfivontinib (G-749) is a potent, oral active and ATP competitive FLT3 inhibitor, with IC50s of 0.4 nM and 0.6 nM for FLT3 wild type and FLT3-D835Y, respectively. Denfivontinib can be used for the research of agent resistance for acute myeloid leukemia (AML) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-W012531
CAS No.: 614-60-8
2-Hydroxycinnamic acid is a phenolic acid with antimicrobial and antioxidant properties. 2-Hydroxycinnamic acid has antimicrobial activity against Staphylococcus aureus and is not susceptible to drug resistance. 2-Hydroxycinnamic acid shows inhibitory effects on infection of HIV/SARS-CoV S pseudovirus with an IC50 of 0.3 mM. In addition, 2-Hydroxycinnamic acid has neuroprotective and antitumor activity .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-150644
CAS No.: 1223194-71-5
Purity:  99.79%
Research Areas:  

Cancer

S07-2010 is a potent pan-AKR1C (aldo-keto reductase family 1 member C) inhibitor, with IC50 values of 0.19, 0.36, 0.47, and 0.73 μM for AKR1C3, AKR1C4, AKR1C1 and AKR1C2, respectively. S07-2010 induces apoptosis in A549/DDP cells. S07-2010 strengthens the cytotoxicity of chemotherapeutic agents in drug-resistant cells. S07-2010 significantly inhibits the proliferation of drug-resistant cells .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-158082C
Synonyms: Tetramethyl rhodamine isothiocyanate glucan, MW 70000
TRITC-dextran MW 70000 (Tetramethyl rhodamine isothiocyanate glucan, MW 70000) is a fluorescent dye with a molecular weight of 70 kD. The excitation wavelength of TRITC-dextran MW 70000 is 555 nm, and its emission wavelength is 570 nm. TRITC-dextran MW 70000 is used for drug delivery because TRITC maintains stability over a wide pH range (i.e., pH 2-11) and exhibits photobleaching resistance .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-144878
CAS No.: 2361742-30-3
Purity:  99.93%
Target:  

c-Myc

Research Areas:  

Cancer

VPC-70619 is a potent N-Myc inhibitor. VPC-70619 blocks the binding of the N-Myc-Max heterocomplex to the DNA E-box and exhibits potent inhibitory activity against N-Myc-dependent cell lines. VPC-70619 can partially reverse paclitaxel (HY-B0015) resistance in cells by reducing MYCN expression. VPC-70619 can be used for cancer research (e.g., neuroblastoma and thyroid cancer) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-158082
Synonyms: Tetramethyl rhodamine isothiocyanate glucan, MW 4000
TRITC-dextran MW 4000 (Tetramethyl rhodamine isothiocyanate glucan, MW 4000) is a fluorescent dye, with the molecular weight of 4 kD. TRITC-dextran MW 4000 exhibits an excitation wavelength of 555 nm. TRITC-dextran MW 4000 is vessel penetrate, which could label blood plasma to visualize the vasculature. TRITC-dextran MW 4000 is utilized in drug delivery for the stability of TRITC over a wide pH range (i.e. pH 2–11) and resistance to photo-bleaching .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-17013A
CAS No.: 153653-30-6
Synonyms: MS-209
Target:  

P-glycoprotein

Research Areas:  

Cancer

Dofequidar fumarate (MS-209) is an orally active quinoline compoundthat blocks P-glycoprotein (P-gp) and multidrug resistance-associated protein-1 (MDR-1). Dofequidar fumarate has highly potent reversing effect on multidrug-resistant tumor cells. Dofequidar fumarate competitively inhibits ABCB1/P-gp, ABCC1/MRP-1, blocks the efflux of chemotherapeutic agents, increases the drug concentration in cancer cells, and enhances the chemotherapeutic effect .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-B1245
CAS No.: 552-94-3
Synonyms: Salicylsalicylic acid; Disalicylic acid
Salsalate is a potent antirheumatic drug with oral activity that reduces irritation during gastric absorption and avoids direct inhibition of cyclooxygenase. Salsalate not only has significant anti-inflammatory effects, but also reduces blood sugar levels, improves insulin resistance, and reduces the expression of cytokines. Salsalate can protect mice from metabolic disorders caused by high-fat diet and effectively improve the symptoms of type 2 diabetes, atherosclerosis and non-alcoholic steatohepatitis [2 ] .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-17013
CAS No.: 129716-58-1
Synonyms: MS-209 free base
Target:  

P-glycoprotein

Research Areas:  

Cancer

Dofequidar (MS-209 free base) is an orally active quinoline compoundthat blocks P-glycoprotein (P-gp) and multidrug resistance-associated protein-1 (MDR-1). Dofequidar has highly potent reversing effect on multidrug-resistant tumor cells. Dofequidar competitively inhibits ABCB1/P-gp, ABCC1/MRP-1, blocks the efflux of chemotherapeutic agents, increases the drug concentration in cancer cells, and enhances the chemotherapeutic effect .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-W018791
CAS No.: 73536-69-3
Synonyms: DDB
Bifendate (DDB), extracted from Schisandrae chinensis, is an orally active anti-HBV agent against chronic hepatitis B. Bifendate inhibits ATG5-dependent autophagy and attenuates oleic acid-induced lipid accumulation with anti-oxidant properties in vitro. Bifendate can decrease alanine transaminase (ALT) level in mice. Bifendate attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Bifendate potently increases the activity of cytochrome proteins (CYPs) and reverse P-gp-mediated multi-drug resistance (MDR) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W067427
CAS No.: 1571-30-8
Target:  

IKK

Research Areas:  

Cancer

BAY32-5915 is a potent IKKα inhibitor with an IC50 value of 60 nM. BAY32-5915 has not affect Doxorubicin (HY-15142A)-induced NF-κB activation .
loading...
    loading...